Qnami secures investment of 4 million Swiss francs
Qnami has raised a total of 4 million Swiss francs from investors after successfully closing a Series A financing round. The Basel Area-based startup has developed a quantum microscope technology that has since been patented as well as producing the first commercial quantum microscope.
The team of Qnami (img: Qnami)
Qnami has announced the successful closing of a Series A financing round in which the startup raised a total of 4 million Swiss francs in fresh capital. Qnami was founded in Basel in 2017 and is now based in Muttenz in the canton of Basel-Landschaft.
The financing round was led by the venture capitalists Runa Capital, which operates out of headquarters in both Silicon Valley and Europe, as well as SIT Capital, which is associated with the Schaffhausen Institute of Technology. The circle of investors included the venture capital companies Quantonation and Verve Ventures, which operate on a pan-European basis, in addition to the Bonn-based High-Tech Gründerfonds and the Cantonal Bank of Zurich.
With this fresh capital injection, Qnami intends to extend its patented quantum microscope technology into applications that will facilitate the design and production of quantum computers and spintronics devices. Furthermore, according to the press release issued by the company, the funds will be used to scale the market launch of the Qnami ProteusQ, the first commercial quantum microscope.
This device uses Qnami’s patented Quantilever diamond scanning probes. “We have gained good market traction with the launch of the ProteusQ and Quantilevers in the materials research setting”, explains Mathieu Munsch, co-founder and CEO of Qnami. “Top researchers already use Qnami’s technology to discover and describe the magnetic properties of new materials”, he adds.
According to Dmitry Galperin, General Partner at Runa Capital, the company is of the view that the technology could also be used for additional applications, including medical imaging and navigation, for example. Galperin is set to join the board of Qnami as a new member.
Share this article
You may also be interested in
RocketVax has found cooperation partners for the development of its innovative coronavirus vaccine. The University Hospital of Basel, the University...Read More
Bright Peak has raised a total of 107 million US dollars as part of a financing round. The biotechnology firm...Read More
Learn more about our AI Program for SMEsRead More